Wrcrcn LLC

1. Pfizer Inc. $1,794,577 232 payments
2. Sanofi Pasteur Inc. $259,618 29 payments
3. Biohaven Pharmaceutical Holding Company Ltd. $25,550 20 payments
4. Organon LLC $6,000 2 payments

1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,032,472 79 payments
2. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $264,212 21 payments
3. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older $211,155 18 payments
4. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $140,837 22 payments
5. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $135,953 22 payments
6. A Phase 3 Singlearm Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age $131,810 12 payments
7. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $74,545 81 payments
8. PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years $42,410 6 payments
9. An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $16,365 9 payments
10. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine 20Vpnc When Coadministered With Seasonal Inactivated Influenza Vaccine Siiv in Adults 65 Years of Age $12,089 2 payments

1. Patient care $6,000 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.